Meaney and O’Keane [7] followed premenopausal female patients with schizophrenia over the course of one year and compared lumbar and femoral BMD changes between those taking prolactin-sparing AP and those taking prolactin-raising AP. The gene discussed is PRL; the disease is schizophrenia.